### Consolidated Results for the Fiscal Year Ended March 31, 2014 (FY2013)

1. Overview

- 2. Financial Position
- 3. Segment Information

May 12, 2014 Ajinomoto Co., Inc.

Hiromichi Oono Member of the Board and Corporate Vice President Ajinomoto Co., Inc.

# **JINOMOTO**. 1. (1) Overview of Results

(¥ Billion)

|   |   |        |        |        |       |                                      |                 |                 |                 | (      | ·····,          |
|---|---|--------|--------|--------|-------|--------------------------------------|-----------------|-----------------|-----------------|--------|-----------------|
|   |   | FY2013 | FY2012 | ΥοΥ ΟΙ | nange | FY2013<br>(Feb. Revised<br>Forecast) | vs.<br>Forecast | JanMar.<br>2014 | JanMar.<br>2013 | YoY C  | hange           |
|   |   | (A)    |        | Amount | %     | (B)                                  | (A)/(B)         |                 |                 | Amount | %               |
| N | et sales                                | 991.3  | 985.0  | 6.4    | 1%    | 1,023.0                              | 97%             | 249.0           | 238.1           | 10.9   | 5%              |
|   | Domestic Food Products                  | 337.5  | 391.6  | -54.0  | -14%  | 338.3                                | 100%            | 82.5            | 77.5            | 5.1    | 7%              |
|   | Overseas Food Products                  | 293.2  | 245.4  | 47.8   | 19%   | 316.2                                | 93%             | 73.8            | 70.1            | 3.8    | 5%              |
|   | Bioscience Products &<br>Fine Chemicals | 228.5  | 204.2  | 24.3   | 12%   | 235.3                                | 97%             | 61.6            | 57.9            | 3.8    | 7%              |
|   | Pharmaceuticals                         | 51.2   | 71.5   | -20.2  | -28%  | 49.0                                 | 105%            | 12.5            | 15.6            | -3.1   | -20%            |
|   | Other Business                          | 80.8   | 72.4   | 8.4    | 12%   | 84.2                                 | 96%             | 18.5            | 17.1            | 1.4    | 8%              |
| 0 | perating income                         | 62.5   | 71.2   | -8.7   | -12%  | 62.0                                 | 101%            | 11.7            | 10.3            | 1.4    | 14%             |
|   | Domestic Food Products                  | 27.4   | 32.6   | -5.2   | -16%  | 26.6                                 | 103%            | 4.7             | 3.5             | 1.2    | 34%             |
|   | Overseas Food Products                  | 25.2   | 20.7   | 4.5    | 22%   | 25.3                                 | 100%            | 5.5             | 5.3             | 0.2    | 4%              |
|   | Bioscience Products &                   | 6.5    | 14.4   | -7.8   | -55%  | 6.4                                  | 102%            | 1.5             | 3.0             | -1.5   | -50%            |
|   | Pharmaceuticals                         | 3.8    | 3.2    | 0.6    | 20%   | 3.3                                  | 116%            | 1.0             | -1.4            | 2.4    | -170%           |
|   | Other Business                          | -0.5   | 0.3    | -0.8   | -250% | 0.4                                  | -122%           | -0.9            | -0.1            | -0.9   | 1,71 <i>2</i> % |
| 0 | rdinary income                          | 69.5   | 77.2   | -7.6   | -10%  | 68.0                                 | 102%            | 12.8            | 11.4            | 1.3    | 12%             |
| N | et income                               | 42.8   | 48.4   | -5.6   | -12%  | 43.0                                 | 100%            | 5.7             | -6.1            | 11.8   | -195%           |
| E | xchange rate JPY/USD                    | 100.17 | 82.91  |        |       | 98.0                                 |                 |                 |                 |        |                 |
|   | JPY/EUR                                 | 134.21 | 106.78 |        |       | 131.0                                |                 |                 |                 |        |                 |

Notes:

1. Jan.-Mar. results are the difference between Apr.-Mar. results and Apr.-Dec. results (for this and all following slides).

2. Changes due to the introduction of net figure (the method of netting off sales and cost of goods sold and recording the net figure in the accounts) for business tie-ups from FY2013 are as follows:

Scope: Kellogg's products included in the "Seasonings & processed foods" category of Domestic Food Products; the "Edible oils" and "Coffee products" categories of Business Tie-Ups

• The former "Business Tie-Ups" segment has been discontinued. "Edible oils" and "Coffee products" have been reclassified as "Edible oils & coffee products" (net figure) in the "Other Business" segment.

• Results for FY2012 have been restated to reflect the above changes (for this and all following slides).

Copyright © 2014 Ajinomoto Co., Inc. All rights reserved.



# **JINOMOTO**. 1. (2) Comments on Results for FY2013

Net sales increased, mainly due to positive effect of currency translation, etc., despite negative effect of disposal of Calpis shares. Operating income decreased because decrease in income of feed-use amino acids, etc. and negative effect of disposal of Calpis shares were not offset by other businesses.

| Net sales         | / Operat | ting inco                                      | me  |   |                                 | (¥ Billion) |
|-------------------|----------|--|---|---|---------------------------------|-------------|
|                   | 5/0040   | VS.  | YoY   |   | JanMar.                         | YoY         |
|                   | FY2013   | Forecast                                       | Change  |   | 2014                            | Change      |
|                   | 991.3    | 97%  | 1%  | Net sales   | 249.0                           | 5%          |
|                   | 635.6    | -  | 6%  | Cost of sales   | 161.7                           | 6%          |
|                   | 293.2    | -  | -6%   | SG&A  | 75.6                            | 1%          |
|                   | 62.5     | 101%   | -12%  | Operating income  | 11.7                            | 14%         |
| ct of<br>ange ra  |          | Full year:<br>Q4:<br>Exchange<br>Full year: \$ | Sales ¥72.8<br>Sales ¥7.1 b<br>rate for trade<br>Sales approx | ency translation<br>billion; operating income ¥6.3<br>illion; operating income ¥0.1<br>e of main overseas subsidiarie<br>x. ¥5.0 billion; operating incom<br>x. ¥1.5 billion; operating incom | billion<br>es<br>ne approx. ¥0. |             |
| of<br>Iterial     | &        |  |   | n raw materials and fuel prices<br>od products raw materials app  |                                 |             |
| prices<br>()      |          | Q4:  | Fermentatio   | n raw materials and fuel price<br>od products raw materials app   | s approx. ¥0.9                  | e billion   |
| st reductio<br>Y) | ons      | -  | Domestic fo   | od products approx. ¥3.3 billio<br>od products approx. ¥0.9 billio<br>Ajinomoto Co., Inc. All rights reserved.  |                                 |             |


# **Live Well. Live Well. JINOMOTO. 1. (3)** Comments on Results for FY2013

| Ordir                             | nary inc                 | ome                                 |   | (¥                                       | Billion)                   |  |
|-----------------------------------|--------------------------|-------------------------------------|---|--|----------------------------|--|
| FY2013                            | vs.<br>Forecast          | YoY<br>Change                       |   | JanMar.<br>2014                          | YoY<br>Change              | < FY2013 > ()= YoY change<br>None  |
| 7.0                               | -                        | 18%                                 | Non-operating<br>income (net)   | 1.0                                      | -8%                        | < Q4 > ( )=YoY change<br>None  |
| 69.5                              | <b>102%</b>              | -10%                                | Ordinary income   | 12.8                                     | 12%                        |  |
| Net in                            | ncome<br>vs.<br>Forecast | YoY<br>Change                       |   | (¥<br>JanMar.<br>2014                    | Billion)<br>YoY<br>Change  | < FY2013 > ()= YoY change<br>*1 Gain on transfer of benefit obligation<br>relating to employees' pension fund<br>¥0.2 billion (¥27.5 billion decrease)<br>*1 Gain on sales of shares in affiliated<br>companies  |
| 8.6<br>4.9<br>23.1<br>7.4<br>42.8 | -                        | -82%<br>-81%<br>-50%<br>11%<br>-12% | Extraordinary gains<br>Extraordinary losses<br>Income taxes, etc.<br>Minority interests<br>Net income | *1 4.8<br>*2 2.1<br>*3 8.0<br>1.7<br>5.7 | 485%<br>-85%<br>171%<br>5% | <ul> <li>¥2.3 billion (¥15.9 billion decrease)</li> <li>*2 Impairment losses</li> <li>¥0.6 billion (¥13.9 billion decrease)</li> <li>*3 Decrease in income taxes, etc. (¥22.7 billion). Factors included:</li> <li>Taxes accrued on disposal of Calpis shares in the previous fiscal year</li> </ul> |
|                                   |                          |                                     |   |  |                            | <ul> <li>Decrease in operation income and<br/>increase in proportion of sales in<br/>regions with low tax rates</li> <li>Tax refund related to transfer pricing</li> <li>&lt; Q4 &gt; ( )=YoY change</li> </ul>  |

Copyright © 2014 Ajinomoto Co., Inc. All rights reserved.

None

# **AJINOMOTO.** 2. Financial Position



Total assets in March 31, 2014 remained at level of previous fiscal year.

#### **Cash Flow**

|                                 |        |        | (¥ Billion) |
|---------------------------------|--------|--------|-------------|
|                                 | FY2013 | FY2012 | Change      |
| 1. CF from operating activities | 63.0   | 88.5   | -25.5       |
| 2. CF from investing activities | -63.5  | 15.2   | -78.7       |
| 3. CF from financing activities | -55.2  | -74.4  | 19.2        |
| 4. Cash and cash equivalents    | 130.0  | 184.8  | -54.7       |
| FCF (1+2)                       | -0.5   | 103.7  | -104.2      |

\*Cash out is shown with -.

| Capital expenditures          | -53.3 | -65.7 | 12.5 |
|-------------------------------|-------|-------|------|
| Depreciation and amortization | 45.7  | 42.5  | 3.3  |


Interest-bearing Debt

|           |           | (¥ Billion) |
|-----------|-----------|-------------|
| Mar. 2014 | Mar. 2013 | Change      |
| 143.0     | 119.3     | 23.6        |

4

Copyright  $\ensuremath{\mathbb{C}}$  2014 Ajinomoto Co., Inc. All rights reserved.

# **JINOMOTO**. 3. (1) Change by Business Segment





# **JINOMOTO**. 3. (2) Domestic Food Products

(¥ Billion)

|        |                 |        |               |                                 | <refer< th=""><th>ence&gt;</th><th colspan="2"></th></refer<> | ence>           |               |  |
|--------|-----------------|--------|---------------|---------------------------------|---|-----------------|---------------|--|
| FY2013 | vs.<br>Forecast | FY2012 | YoY<br>Change |                                 | JanMar.<br>2014   | JanMar.<br>2013 | YoY<br>Change |  |
| 337.5  | 100%            | 391.6  | -54.0         | Net sales                       | 82.5  | 77.5            | 5.1           |  |
| 217.4  | -               | 217.4  | -0.0          | *1 Seasonings & processed foods | 53.2  | 49.8            | 3.4           |  |
| 120.1  | -               | 114.8  | 5.4           | *2 Frozen foods                 | 29.4  | 27.7            | 1.7           |  |
| 0.0    | -               | 59.4   | -59.4         | Beverages ("Calpis")            | 0.0   | 0.0             | 0.0           |  |
| 27.4   | 103%            | 32.6   | -5.2          | *3 Operating income             | 4.7   | 3.5             | 1.2           |  |
| 29.6   | -               | 29.4   | 0.2           | Seasonings & processed foods    | 5.6   | 4.7             | 0.9           |  |
| 5.4    | -               | 7.5    | -2.1          | Frozen foods                    | 1.2   | 0.7             | 0.4           |  |
| 0.0    | -               | 4.8    | -4.8          | Beverages ("Calpis")            | 0.0   | -0.0            | 0.0           |  |
| -7.6   | 100%            | -9.1   | 1.5           | Shared companywide expenses     | -2.1  | -1.9            | -0.2          |  |

\*1 Sales remained at level of previous fiscal year due to last-minute demand in advance of increase in consumption tax rate in addition to contribution of new home-use products launched in previous fiscal year, despite negative effect of end of sales of beverage gifts resulting from disposal of Calpis shares.

- \*2 Increase in sales due to firm sales in Japan and significant expansion of sales overseas with growth in North America and positive effect of currency translation.
- \*3 Decrease in operating income due to effect of disposal of Calpis shares and lower income of frozen foods due to weaker yen and higher raw material prices, etc., despite higher income of seasonings & processed foods.

### **JINOMOTO**. 3. (3) Overseas Food Products

(¥ Billion)

|        |                 |        |               |  | <refer< th=""><th>ence&gt;</th><th></th></refer<> | ence>           |               |
|--------|-----------------|--------|---------------|--|---|-----------------|---------------|
| FY2013 | vs.<br>Forecast | FY2012 | YoY<br>Change |  | JanMar.<br>2014                                   | JanMar.<br>2013 | YoY<br>Change |
| 293.2  | 93%             | 245.4  | 47.8          | Net sales                                      | 73.8  | 70.1            | 3.8           |
| 241.8  | -               | 199.3  | 42.5*         | 1 Consumer foods                               | 60.6  | 57.1            | 3.5           |
| 51.4   | -               | 46.1   | 5.3 *         | 2 Umami seasonings for<br>processed food mfrs. | 13.2  | 12.9            | 0.3           |
| 25.2   | 100%            | 20.7   | 4.5           | <sup>3</sup> Operating income                  | 5.5   | 5.3             | 0.2           |
| -9.5   | 100%            | -8.0   | -1.4          | Shared companywide expenses                    | -2.8  | -2.4            | -0.4          |

[Effect of currency translation] FY2013: Net sales +¥39.8 billion; operating income +¥4.7 billion Q4: Net sales +¥2.1 billion; operating income -¥0.1 billion

- \*1 Increase in sales because of positive effect of currency translation and higher sales volume of umami seasoning *AJI-NO-MOTO*, flavor seasonings and instant noodles, etc.
- \*2 Increase in sales because of positive effect of currency translation and higher sales volume of MSG, despite decrease in unit price.
- \*3 Increase in income as higher income of consumer foods (\*1) offset decrease in unit price of umami seasonings for processed food mfrs.

Reference (vs. previous fiscal year):

Consumer foods +¥7.5 billion; umami seasonings for processed food mfrs. -¥1.3 billion

# **JINOMOTO.** 3. (4) Bioscience Products & Fine Chemicals

| FY2013 | vs.<br>Forecast | FY2012 | YoY<br>Change |                                | JanMar.<br>2014 | JanMar.<br>2013 | ( <b>¥ Billion)</b><br>YoY<br>Change |
|--------|-----------------|--------|---------------|--------------------------------|-----------------|-----------------|--------------------------------------|
| 228.5  | 97%             | 204.2  | 24.3          | Net sales                      | 61.6            | 57.9            | 3.8                                  |
| 94.1   | 97%             | 94.1   | 0.1           | *1 Feed-use amino acids        | 22.2            | 25.2            | -3.0                                 |
| 86.1   | -               | 66.7   | 19.4          | *2 Amino acids                 | 28.1            | 21.5            | 6.5                                  |
| 43.1   | -               | 38.2   | 4.9           | *3 Specialty chemicals         | 10.1            | 9.6             | 0.6                                  |
| 6.5    | <b>102%</b>     | 14.4   | -7.8          | <sup>*4</sup> Operating income | 1.5             | 3.0             | -1.5                                 |
| 0.2    | -               | 13.5   | -13.3         | Feed-use amino acids           | -0.5            | 3.0             | -3.5                                 |
| 5.5    | -               | 2.5    | 3.0           | Amino acids                    | 2.6             | 0.6             | 2.0                                  |
| 9.3    | -               | 6.5    | 2.8           | Specialty chemicals            | 2.0             | 1.6             | 0.4                                  |
| -6.8   | 105%            | -5.8   | -1.0          | Shared companywide expenses    | -2.0            | -1.7            | -0.4                                 |

[Effect of currency translation] FY2013: Net sales +¥28.1 billion; operating income +¥0.9 billion

Q4: Net sales +¥4.4 billion; operating income +¥0.2 billion

- \*1 Sales remained at level of previous fiscal year because of decrease in unit price, despite positive effect of currency translation.
- \*2 Amino acids for pharmaceuticals and foods +¥6.6 billion; pharmaceutical custom manufacturing +¥11.6 billion; sweeteners +¥1.2 billion.
- \*3 Sales of both chemicals and cosmetics and cosmetic ingredients increased.
- \*4 Decrease in income because higher income of amino acids and specialty chemicals did not offset lower income of feed-use amino acids, etc.
  - Reference (vs. previous fiscal year):

Within amino acids, amino acids for pharmaceuticals and foods +¥2.0 billion; pharmaceutical custom manufacturing -¥0.0. billion; sweeteners +¥1.1 billion

# **AJINOMOTO.** 3. (5) Pharmaceuticals

(¥ Billion)

|        |                 |        |               | <reference></reference>     |                 |                 |               |  |  |
|--------|-----------------|--------|---------------|-----------------------------|-----------------|-----------------|---------------|--|--|
| FY2013 | vs.<br>Forecast | FY2012 | YoY<br>Change |                             | JanMar.<br>2014 | JanMar.<br>2013 | YoY<br>Change |  |  |
| 51.2   | 105%            | 71.5   | -20.2 *       | 1 Net sales                 | 12.5            | 15.6            | -3.1          |  |  |
| 3.8    | 116%            | 3.2    | <b>0.6</b> *2 | 2 Operating income          | 1.0             | -1.4            | 2.4           |  |  |
| -1.4   | 103%            | -1.9   | 0.5 S         | Shared companywide expenses | -0.4            | -0.5            | 0.1           |  |  |

\*1 Decrease in sales of self-distributed products due to impact of spin-off of infusion and dialysis business units as AY PHARMACEUTICALS Co., Ltd. in July 2013 (approx. ¥ 14.6 billion) and change of segment for medical foods (Pharmaceuticals → Other Business) (approx. ¥ 3.3 billion). Sales of products sold through business tie-ups decreased because of growth of competing products, including generics.

Sales based on AJINOMOTO PHARMACEUTICALS CO., LTD. estimated drug prices

(% = change from previous fiscal year):

| LIVACT | ¥14.8 billion | (-1%)  | ELENTAL | ¥7.7 billion  | (0%)   |
|--------|---------------|--------|---------|---------------|--------|
| ATELEC | ¥14.6 billion | (-3%)  | ACTONEL | ¥10.0 billion | (-14%) |
| FASTIC | ¥1.8 billion  | (-26%) |         |               |        |

\*2 Increase in income due to improvement of operation efficiency, despite lower income of products sold through business tie-ups because of lower sales.



# **Eat Well, Live Well. 3. (6) Other Business**

|        |                 |        |               |                               |   | (¥              | Billion)      |
|--------|-----------------|--------|---------------|-------------------------------|---|-----------------|---------------|
|        |                 |        |               |                               | <refer< th=""><th>ence&gt;</th><th></th></refer<> | ence>           |               |
| FY2013 | vs.<br>Forecast | FY2012 | YoY<br>Change |                               | JanMar.<br>2014                                   | JanMar.<br>2013 | YoY<br>Change |
| 80.8   | 96%             | 72.4   | 8.4           | *1 Net sales                  | 18.5  | 17.1            | 1.4           |
| 2.3    | -               | 2.2    | 0.1           | Edible oils & coffee products | 0.6   | 0.5             | 0.0           |
| -0.5   | -114%           | 0.3    | -0.8          | *2 Operating income           | -0.9  | -0.1            | -0.9          |
| 2.2    | -               | 2.1    | 0.1           | Edible oils & coffee products | 0.5   | 0.5             | 0.0           |
| -3.0   | 96%             | -2.7   | -0.2          | Shared companywide expenses   | -0.8  | -0.7            | -0.2          |

\*1 Increase in sales due to impact of change of segment for medical foods (Pharmaceuticals → Other Business) and increase in orders in the engineering business, etc.

\*2 Decrease in income due to lower income of logistics business, etc., despite higher income in wellness business.



# Eat Well, Live Well. **3. (7)**

# 3. (7) Net Sales by Business & Geographical Area

Upper row: FY2013; lower row: FY2012 Figures in parentheses represent YoY change.

(¥ Billion)

|                            | Japan |         | Asia  |        | Americas |        | Europe |        | Total |         |
|----------------------------|-------|---------|-------|--------|----------|--------|--------|--------|-------|---------|
| Domestic Food              | 317.8 | (-57.6) | 5.4   | (-0.4) | 12.6     | (3.7)  | 1.7    | (0.4)  | 337.5 | (-54.0) |
| Products                   | 375.5 |         | 5.8   |        | 8.9      |        | 1.3    |        | 391.6 |         |
| Overseas Food<br>Products  | 9.5   | (-0.1)  | 198.3 | (33.3) | 54.6     | (9.7)  | 30.8   | (4.9)  | 293.2 | (47.8)  |
|                            | 9.6   |         | 165.0 |        | 44.9     |        | 25.9   |        | 245.4 |         |
| <b>Bioscience Products</b> | 64.3  | (7.1)   | 17.8  | (2.5)  | 72.0     | (8.4)  | 74.3   | (6.4)  | 228.5 | (24.3)  |
| & Fine Chemicals           | 57.2  |         | 15.3  |        | 63.6     |        | 68.0   |        | 204.2 |         |
| Pharmaceuticals            | 51.2  | (-20.2) |       |        |          |        |        |        | 51.2  | (-20.2) |
|                            | 71.5  |         |       |        |          |        |        |        | 71.5  |         |
| Other Business             | 71.2  | (7.5)   | 9.6   | (0.9)  | 0.1      | (0.0)  |        |        | 80.8  | (8.4)   |
|                            | 63.7  |         | 8.6   |        | 0.0      |        |        |        | 72.4  |         |
| Total                      | 514.0 | (-63.4) | 231.1 | (36.3) | 139.3    | (21.8) | 106.9  | (11.7) | 991.3 | (6.4)   |
| TOLAT                      | 577.5 | . ,     | 194.8 |        | 117.5    |        | 95.2   | . ,    | 985.0 |         |



# Eat Well, Live Well.

### 3. (8) Operating Income by Business & Geographical Area

### Upper row: FY2013; lower row: FY2012 Figures in parentheses represent YoY change.

(¥ Billion)

|                                       | Jap   | an     | As   | ia     | Amer | icas   | Euro | ope    | Oth   | er <sup>*</sup> | Tot  | al     |
|---------------------------------------|-------|--------|------|--------|------|--------|------|--------|-------|-----------------|------|--------|
| Domestic Food                         | 31.5  | (-8.0) | 1.9  | (0.8)  | 1.4  | (0.4)  | 0.4  | (0.1)  | -7.7  | (1.5)           | 27.4 | (-5.2) |
| Products                              | 39.5  |        | 1.0  |        | 1.0  |        | 0.2  |        | -9.2  |                 | 32.6 |        |
| Overseas Food                         | -1.3  | (0.7)  | 29.5 | (4.8)  | 7.5  | (2.4)  | -0.7 | (-1.6) | -9.8  | (-1.8)          | 25.2 | (4.5)  |
| Products                              | -2.0  |        | 24.7 |        | 5.1  |        | 0.9  |        | -8.0  |                 | 20.7 |        |
| <b>Bioscience Products &amp; Fine</b> | 10.2  | (5.5)  | 0.5  | (-1.7) | -0.4 | (-7.0) | 3.6  | (-3.6) | -7.4  | (-1.1)          | 6.5  | (-7.8) |
| Chemicals                             | 4.7   |        | 2.2  |        | 6.6  |        | 7.2  |        | -6.3  |                 | 14.4 |        |
| Pharmaceuticals                       | 5.3   | (0.2)  |      |        |      |        |      |        | -1.4  | (0.5)           | 3.8  | (0.6)  |
|                                       | 5.1   |        |      |        |      |        |      |        | -1.9  |                 | 3.2  |        |
| Other Business                        | 1.8   | (-0.6) | 0.9  | (0.1)  | 0.0  | (-0.0) | 0.1  | (0.0)  | -3.3  | (-0.4)          | -0.5 | (-0.8) |
|                                       | 2.4   |        | 0.8  |        | 0.0  |        | 0.1  |        | -2.9  |                 | 0.3  |        |
| Shared companywide                    | -14.3 | (1.0)  | -7.8 | (-1.2) | -4.2 | (-0.8) | -3.2 | (-0.4) | -29.6 | (-1.3)          |      |        |
| expenses, etc.*                       | -15.4 |        | -6.6 |        | -3.4 |        | -2.9 |        | -28.3 |                 |      |        |
| Total                                 | 33.2  | (-1.2) | 25.0 | (2.9)  | 4.3  | (-5.0) | 0.1  | (-5.4) |       |                 | 62.5 | (-8.7) |
| Total                                 | 34.4  |        | 22.1 |        | 9.3  |        | 5.5  | -      |       |                 | 71.2 |        |

\* Shared companywide expenses and unrealized gains and losses not reflected in any geographical area, etc.



# Eat Well, Live Well.3. (9) Comments on Operating Income byJINOMOTO.Business & Geographical Area

### FY2013 Change Compared with FY2012

### **1. Overseas Food Products**

[YoY change]

(¥ Billion)

Japan +0.7; Asia +4.8; Americas +2.4; Europe -1.6; Other\* -1.8; Total +4.5

Asia: Increase due to positive effect of currency translation and higher sales of consumer foods products

### 2. Bioscience Products & Fine Chemicals

[YoY change]

(¥ Billion)

Japan +5.5; Asia -1.7; Americas -7.0; Europe -3.6; Other\* -1.1; Total -7.8

Japan: Increase due to specialty chemicals and amino acids, etc.

America: Decrease due to feed-use amino acids, etc.

\* Shared companywide expenses and unrealized gains and losses not reflected in any geographical area, etc.



### Eat Well, Live Well. FY2011-2013 Medium-Term Management Plan: Review of KPIs

"Business Structure Reinforcement" Proceeding Smoothly, But Only Partial Results for "Growth"

|                                     |  | Qualitative Evaluation  | KPI  | FY2010                                       | FY11-13<br>Medium-Term<br>Plan Target | FY2013                         |
|-------------------------------------|--|---|--|--|---------------------------------------|--------------------------------|
| 1<br>Deployment                     | Global<br>growth   | <ul> <li>Overseas Food Products grew in ASEAN<br/>and South America, expanded bases in<br/>emerging countries</li> <li>3 bulk businesses<sup>1</sup> faced intense competition</li> </ul> | Companywide<br>overseas sales ratio<br>Companywide<br>overseas profit ratio            |  | 35%<br>56%                            | 48%<br>47%                     |
| of growth<br>drivers                | R&D<br>leadership  |   | Ratio of R&D investmen<br>in future domains within<br>total R&D investment             |  | 40%                                   | 45%                            |
| 2                                   | From volume<br>to value  | <ul> <li>Transformed the earnings structure<br/>through structural reform</li> <li>Further transformation to added value<br/>in progress through pursuit of specialty</li> </ul>          | Operating profit<br>O.P. margin<br>Sales ratio of value-ado<br>businesses <sup>2</sup> | <b>¥</b> 69.4B<br><sub>ded</sub> 5.7%<br>70% | ¥87.0B<br>Up to 7%<br>80%+            | <b>¥</b> 62.5B<br>6.3%<br>100% |
| Business<br>structure<br>reinforce- | From profit<br>to cash   | <ul> <li>Generated free cash flow by curtailing capital investment</li> <li>Proactively used M&amp;A for growth</li> </ul>  | Free cash flow   | <b>¥</b> 66.8B/yr                            | <b>. ¥</b> 40.0B/yr.                  | <b>-¥</b> 0.5 B/yr.            |
|                                     | Enhance<br>capital efficiency<br>to boost<br>stockholder value | did not reach target  | t ROE  | 5.0%   | 8%                                    | 7.1%                           |
| 3<br>Foundation<br>building         | Global HR<br>development                                       | <ul> <li>Promoted diverse HR mix</li> <li>Built Group HR platform</li> <li>Conducted training on the<br/>Ajinomoto Group Way</li> </ul>   | Local executive ratio<br>in foreign enterprises  | 34%  | 50%                                   | 40%                            |

1) 3 bulk businesses: Umami seasonings for processed food manufacturers, sweeteners, feed-use amino acids

2) Sales ratio of value-added businesses: Based on total sales excluding 3 bulk businesses

Copyright © 2014 Ajinomoto Co., Inc. All rights reserved.



#### **Eat Well, Live Well.** Change in Standard for Recording Net Sales from FY2014 (Planned)

From FY2014, sales promotion discounts, etc. will be deducted from net sales rather than being recorded in SG&A expenses. In addition, under this accounting treatment the estimated amount will be recorded when sales are recorded rather than when the amount to be paid is determined.

Change in Presentation of Sales Promotion Discounts, etc.

Until FY2013 Recorded as sales commissions

From FY2014 Deducted from net sales

• Impact on FY2013 Results (\*)

Net sales - ¥39.3 billion

Operating income ¥ 0.0 billion

 The business with the largest impact is the home-use business in Domestic Food Products, but there is also some impact on overseas consumer foods, sweeteners and Other Business (wellness foods).

Change in Timing of Recording Sales Promotion Discounts, etc.

- Until FY2013 Recorded when amount to be paid is determined
- From FY2014 Estimated amount recorded when sales are recorded

\* Note: Restated figures for FY2013 are unaudited and the retroactive application of the new accounting method is not complete. The figures are therefore subject to change. Definitive figures are scheduled to be announced at the time of the announcement of first-quarter results.



# Eat Well, Live Well.

- Forward-looking statements, such as business performance forecasts, made in these materials are based on management's estimates, assumptions and projections at the time of publication and do not represent a commitment from Ajinomoto Co., Inc. that they will be achieved. A number of factors could cause actual results to differ materially from expectations.
- > Unaudited figures are included in these materials for reference.
- > Amounts presented in these materials are rounded off.